Skip to main content
Top

Open Access 04-05-2024 | Positron Emission Tomography | Original Article

Maximum standardized uptake value in 11C-methionine positron emission tomography may predict the prognosis of patients with oral squamous cell carcinoma

Authors: Takeshi Kuroshima, Yoshimasa Kitagawa, Jun Sato, Shiro Watanabe, Takuya Asaka, Takahiro Abe, Hiroyuki Harada, Kenji Hirata, Yuji Kuge

Published in: Odontology

Login to get access

Abstract

The present study aimed to elucidate the correlation between the uptake of 11C-methionine (MET) by a primary tumor and the survival of patients with oral squamous cell carcinoma (OSCC). This study enrolled 31 patients who underwent radical surgery for OSCC. The patients underwent pretreatment MET-positron emission tomography (PET) scanning. We analyzed correlations between the maximum standardized uptake value (SUVmax) of MET-PET in a primary tumor and the clinicopathological features. Further, we compared overall survival (OS), disease-specific survival (DSS), and loco-regional recurrence (LRR) rates between the two groups according to SUVmax of MET-PET. SUVmax of MET-PET in a primary tumor was higher in patients with advanced T-classification and advanced clinical stage, with significant differences (P = 0.001 and P = 0.016, respectively). The patients with SUVmax of MET-PET ≥ 4.4 showed significantly lower DSS rates and higher LRR rates than those with SUVmax of < 4.4 (P = 0.015 and P = 0.016, respectively). SUVmax of MET-PET and OS rates showed no significant correlation (P = 0.073). The present study revealed that SUVmax of MET-PET may predict clinical outcomes and prognosis in patients with OSCC who underwent radical surgery.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Can J Clin. 2018;68:394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Can J Clin. 2018;68:394–424.CrossRef
2.
go back to reference Sato J, Kitagawa Y, Watanabe S, Asaka T, Ohga N, Hirata K, et al. Hypoxic volume evaluated by 18F-fluoromisonidazole positron emission tomography (FMISO-PET) may be a prognostic factor in patients with oral squamous cell carcinoma: preliminary analyses. Int J Oral Maxillofac Surg. 2018;47:553–60.CrossRefPubMed Sato J, Kitagawa Y, Watanabe S, Asaka T, Ohga N, Hirata K, et al. Hypoxic volume evaluated by 18F-fluoromisonidazole positron emission tomography (FMISO-PET) may be a prognostic factor in patients with oral squamous cell carcinoma: preliminary analyses. Int J Oral Maxillofac Surg. 2018;47:553–60.CrossRefPubMed
4.
go back to reference Yonezawa N, Minamikawa T, Kitajima K, Takahashi Y, Sasaki R, Nibu KI, et al. The maximum standardized uptake value increment calculated by dual-time-point (18) F-fluorodeoxyglucose positron emission tomography predicts survival in patients with oral tongue squamous cell carcinoma. Nagoya J Med Sci. 2017;79:189–98.PubMedPubMedCentral Yonezawa N, Minamikawa T, Kitajima K, Takahashi Y, Sasaki R, Nibu KI, et al. The maximum standardized uptake value increment calculated by dual-time-point (18) F-fluorodeoxyglucose positron emission tomography predicts survival in patients with oral tongue squamous cell carcinoma. Nagoya J Med Sci. 2017;79:189–98.PubMedPubMedCentral
5.
go back to reference Uchiyama Y, Hirata K, Watanabe S, Okamoto S, Shiga T, Okada K, et al. Development and validation of a prediction model based on the organ-based metabolic tumor volume on FDG-PET in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2021;35:1223–31.CrossRefPubMed Uchiyama Y, Hirata K, Watanabe S, Okamoto S, Shiga T, Okada K, et al. Development and validation of a prediction model based on the organ-based metabolic tumor volume on FDG-PET in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2021;35:1223–31.CrossRefPubMed
6.
go back to reference Hsieh HJ, Lin SH, Lin KH, Lee CY, Chang CP, Wang SJ. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET. Ann Nucl Med. 2008;22:533–8.CrossRefPubMed Hsieh HJ, Lin SH, Lin KH, Lee CY, Chang CP, Wang SJ. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET. Ann Nucl Med. 2008;22:533–8.CrossRefPubMed
7.
go back to reference Kawase Y, Yamamoto Y, Kameyama R, Kawai N, Kudomi N, Nishiyama Y. Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma. Mol Imag Biol. 2011;13:1284–9.CrossRef Kawase Y, Yamamoto Y, Kameyama R, Kawai N, Kudomi N, Nishiyama Y. Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma. Mol Imag Biol. 2011;13:1284–9.CrossRef
8.
go back to reference Okochi Y, Nihashi T, Fujii M, Kato K, Okada Y, Ando Y, et al. Clinical use of (11) C-methionine and (18) F-FDG-PET for germinoma in central nervous system. Ann Nucl Med. 2014;28:94–102.CrossRefPubMed Okochi Y, Nihashi T, Fujii M, Kato K, Okada Y, Ando Y, et al. Clinical use of (11) C-methionine and (18) F-FDG-PET for germinoma in central nervous system. Ann Nucl Med. 2014;28:94–102.CrossRefPubMed
9.
go back to reference Maffione AM, Grassetto G, Rampin L, Chondrogiannis S, Marzola MC, Ambrosini V, et al. Molecular imaging of pulmonary nodules. AJR Am J Roentgenol. 2014;202:217–23.CrossRef Maffione AM, Grassetto G, Rampin L, Chondrogiannis S, Marzola MC, Ambrosini V, et al. Molecular imaging of pulmonary nodules. AJR Am J Roentgenol. 2014;202:217–23.CrossRef
10.
go back to reference Nakajima R, Kimura K, Abe K, Sakai S. 11C-methionine PET/CT findings in benign brain disease. Jpn J Radiol. 2017;35:279–88.CrossRefPubMed Nakajima R, Kimura K, Abe K, Sakai S. 11C-methionine PET/CT findings in benign brain disease. Jpn J Radiol. 2017;35:279–88.CrossRefPubMed
11.
go back to reference Lindholm P, Leskinen-Kallio S, Minn H, Bergman J, Haaparanta M, Lehikoinen P, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J Nucl Med. 1993;34:1711–6.PubMed Lindholm P, Leskinen-Kallio S, Minn H, Bergman J, Haaparanta M, Lehikoinen P, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J Nucl Med. 1993;34:1711–6.PubMed
12.
go back to reference Lindholm P, Leskinen-Kallio S, Grénman R, Lehikoinen P, Någren K, Teräs M, et al. Evaluation of response to radiotherapy in head and neck cancer by positron emission tomography and 11C-methionine. Int J Radiat Oncol Biol Phys. 1995;32:787–94.CrossRefPubMed Lindholm P, Leskinen-Kallio S, Grénman R, Lehikoinen P, Någren K, Teräs M, et al. Evaluation of response to radiotherapy in head and neck cancer by positron emission tomography and 11C-methionine. Int J Radiat Oncol Biol Phys. 1995;32:787–94.CrossRefPubMed
13.
go back to reference Lindholm P, Leskinen S, Lapela M. Carbon-11-methionine uptake in squamous cell head and neck cancer. J Nucl Med. 1998;39:1393–7.PubMed Lindholm P, Leskinen S, Lapela M. Carbon-11-methionine uptake in squamous cell head and neck cancer. J Nucl Med. 1998;39:1393–7.PubMed
14.
go back to reference Leskinen-Kallio S, Någren K, Lehikoinen P, Ruotsalainen U, Teräs M, Joensuu H. Carbon-11-methionine and PET is an effective method to image head and neck cancer. J Nucl Med. 1992;33:691–5.PubMed Leskinen-Kallio S, Någren K, Lehikoinen P, Ruotsalainen U, Teräs M, Joensuu H. Carbon-11-methionine and PET is an effective method to image head and neck cancer. J Nucl Med. 1992;33:691–5.PubMed
15.
go back to reference Kobayashi K, Hirata K, Yamaguchi S, Manabe O, Terasaka S, Kobayashi H, et al. Prognostic value of volume-based measurements on (11) C-methionine PET in glioma patients. Eur J Nucl Med Mol Imag. 2015;42:1071–80.CrossRef Kobayashi K, Hirata K, Yamaguchi S, Manabe O, Terasaka S, Kobayashi H, et al. Prognostic value of volume-based measurements on (11) C-methionine PET in glioma patients. Eur J Nucl Med Mol Imag. 2015;42:1071–80.CrossRef
16.
go back to reference Yamaguchi S, Hirata K, Okamoto M, Shimosegawa E, Hatazawa J, Hirayama R, et al. Determination of brain tumor recurrence using 11 C-methionine positron emission tomography after radiotherapy. Can Sci. 2021;112:4246–56.CrossRef Yamaguchi S, Hirata K, Okamoto M, Shimosegawa E, Hatazawa J, Hirayama R, et al. Determination of brain tumor recurrence using 11 C-methionine positron emission tomography after radiotherapy. Can Sci. 2021;112:4246–56.CrossRef
17.
go back to reference Miyazawa H, Arai T, Iio M, Hara T. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med. 1993;34:1886–91.PubMed Miyazawa H, Arai T, Iio M, Hara T. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med. 1993;34:1886–91.PubMed
18.
go back to reference Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med. 1993;34:1936–43.PubMed Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med. 1993;34:1936–43.PubMed
19.
go back to reference Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti AA, editors. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2009. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti AA, editors. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2009.
20.
go back to reference Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, et al. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med. 2001;28:155–64.CrossRefPubMed Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, et al. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med. 2001;28:155–64.CrossRefPubMed
21.
go back to reference Yamamoto F, Tsukamoto E, Nakada K, Takei T, Zhao S, Asaka M, et al. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-hodgkin’s lymphoma. Ann Nucl Med. 2004;18:519–26.CrossRefPubMed Yamamoto F, Tsukamoto E, Nakada K, Takei T, Zhao S, Asaka M, et al. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-hodgkin’s lymphoma. Ann Nucl Med. 2004;18:519–26.CrossRefPubMed
22.
go back to reference Kito S, Koga H, Kodama M, Habu M, Kokuryo S, Yamamoto N, et al. Variety and complexity of fluorine-18-labelled fluoro-2-deoxy-d-glucose accumulations in the oral cavity of patients with oral cancers. Dentomaxillofac Radiol. 2013;42:20130014.CrossRefPubMedPubMedCentral Kito S, Koga H, Kodama M, Habu M, Kokuryo S, Yamamoto N, et al. Variety and complexity of fluorine-18-labelled fluoro-2-deoxy-d-glucose accumulations in the oral cavity of patients with oral cancers. Dentomaxillofac Radiol. 2013;42:20130014.CrossRefPubMedPubMedCentral
23.
go back to reference Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104–12.PubMed Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104–12.PubMed
24.
go back to reference Chan SC, Hsu CL, Yen TC, Ng SH, Liao CT, Wang HM. The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2013;49:71–8.CrossRefPubMed Chan SC, Hsu CL, Yen TC, Ng SH, Liao CT, Wang HM. The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2013;49:71–8.CrossRefPubMed
25.
go back to reference Ryu IS, Kim JS, Roh JL, Cho KJ, Choi SH, Nam SY, et al. Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by (18) F-FDG PET/CT in squamous cell carcinoma of the oral cavity. Eur J Nucl Med Mol Imag. 2014;41:452–61.CrossRef Ryu IS, Kim JS, Roh JL, Cho KJ, Choi SH, Nam SY, et al. Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by (18) F-FDG PET/CT in squamous cell carcinoma of the oral cavity. Eur J Nucl Med Mol Imag. 2014;41:452–61.CrossRef
26.
27.
go back to reference Kubota R, Kubota K, Yamada S, Tada M, Takahashi T, Iwata R, et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med. 1995;36:484–92.PubMed Kubota R, Kubota K, Yamada S, Tada M, Takahashi T, Iwata R, et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med. 1995;36:484–92.PubMed
28.
go back to reference Kanegae K, Nakano I, Kimura K, Kaji H, Kuge Y, Shiga T, et al. Comparison of MET-PET and FDG-PET for differentiation between benign lesions and lung cancer in pneumoconiosis. Ann Nucl Med. 2007;21:331–7.CrossRefPubMed Kanegae K, Nakano I, Kimura K, Kaji H, Kuge Y, Shiga T, et al. Comparison of MET-PET and FDG-PET for differentiation between benign lesions and lung cancer in pneumoconiosis. Ann Nucl Med. 2007;21:331–7.CrossRefPubMed
29.
go back to reference Goksel S, Erdivanli OC, Bulbul O, Dursun E. The role of metabolic tumor parameters predicting cervical lymph node metastasis in patients with head and neck squamous cell carcinoma. J Can Res Ther. 2022;18:1045–51.CrossRef Goksel S, Erdivanli OC, Bulbul O, Dursun E. The role of metabolic tumor parameters predicting cervical lymph node metastasis in patients with head and neck squamous cell carcinoma. J Can Res Ther. 2022;18:1045–51.CrossRef
30.
go back to reference Yamada T, Uchida M, Kwang-Lee K, et al. Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:464–71.CrossRefPubMed Yamada T, Uchida M, Kwang-Lee K, et al. Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:464–71.CrossRefPubMed
Metadata
Title
Maximum standardized uptake value in 11C-methionine positron emission tomography may predict the prognosis of patients with oral squamous cell carcinoma
Authors
Takeshi Kuroshima
Yoshimasa Kitagawa
Jun Sato
Shiro Watanabe
Takuya Asaka
Takahiro Abe
Hiroyuki Harada
Kenji Hirata
Yuji Kuge
Publication date
04-05-2024
Publisher
Springer Nature Singapore
Published in
Odontology
Print ISSN: 1618-1247
Electronic ISSN: 1618-1255
DOI
https://doi.org/10.1007/s10266-024-00946-w